News | April 28, 2023
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
The business and product range of Ipca and that of Unichem complements each others business and product range
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Fully equipped labs with 75-member team set-up and made operational in <100 days
Subscribe To Our Newsletter & Stay Updated
